HUP0104607A2 - MEK inhibitor alkalmazása transzplantátumok kilökődésének megelőzésére - Google Patents
MEK inhibitor alkalmazása transzplantátumok kilökődésének megelőzéséreInfo
- Publication number
- HUP0104607A2 HUP0104607A2 HU0104607A HUP0104607A HUP0104607A2 HU P0104607 A2 HUP0104607 A2 HU P0104607A2 HU 0104607 A HU0104607 A HU 0104607A HU P0104607 A HUP0104607 A HU P0104607A HU P0104607 A2 HUP0104607 A2 HU P0104607A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- hydrogen atom
- alkyl
- atom
- hydroxyl
- Prior art date
Links
- 229940124647 MEK inhibitor Drugs 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- PLXPTFQGYWXIEA-UHFFFAOYSA-N nitroformonitrile Chemical compound [O-][N+](=O)C#N PLXPTFQGYWXIEA-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010040844 Skin exfoliation Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000004299 exfoliation Methods 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
A tal lm ny t rgya elj r s emlős"kben tültetett szervek, sejtek,végtagok és sz"vetek kil"kődésének gyógyító vagy megelőző kezelésére,amely elj r s szerint szelektív MEK inhibitort, előny"sen (I) vagy(II) ltal nos képletű vegyületet adagolunk. A képletekben R1 jelentésehidrogénatom, hidroxil-, 1-8 szénatomos alkil-, 1-8 szénatomosalkoxicsoport, halogénatom, trifluorometil-, vagy cianidcsoport. R2jelentése hidrogénatom. R3, R4 és R5 jelentése egym stól függetlenülhidrogénatom, hidroxilcsoport, halogénatom, trifluorometil-, 1-8szénatomos alkil-, 1-8 szénatomos alkoxi-, nitro-, cianid-, vagy -(Ovagy NH)m-(CH2)n-R9 képletű csoport. R9 jelentése hidrogénatom,hidroxil-, karboxil-, vagy NR10R11 képletű csoport; n értéke 0 és 4k"z"tti sz m; m értéke 0 vagy 1. R10 és R11 jelentése egyar nt, egymstól függetlenül hidrogénatom és 1-8 szénatomos alkilcsoport, R1ajelentése hidrogénatom, hidroxil-, 1-8 szénatomos alkil-, 1-8szénatomos alkoxicsoport, halogénatom, trifluoro-metil-, vagycianidcsoport. R2a jelentése hidrogénatom. R3a, R4a, és R5a jelentéseegyar nt, egym stól függetlenül hidrogénatom, hidroxilcsoport,halogénatom, trifluoro-metil-, 1-8 szénatomos alkil-, 1-8 szénatomosalkoxi-, nitro-, cianidcsoport, vagy (O vagy NH)m-(CH2)n-R9a-képletűcsoport. R9a jelentése hidrogénatom, hidroxil-, CO2H-, vagy NR10aR11a-képletű csoport; n értéke 0-4 k"z"tti sz m; és m értéke 0 vagy 1. R6ajelentése hidrogénatom, 1-8 szénatomos alkil-, (CO)-(1-8 szénatomosalkil)-csoport, aril-, aralkil-, vagy 3-10 szénatomoscikloalkilcsoport. R7a jelentése hidrogénatom, 1-8 szénatomos alkil-,2-8 szénatomos alkenil-, 2-8 szénatomos alkinil-, 3-10 szénatomos(cikloalkil vagy adott esetben egy heteroatommal helyettesítettcikloalkil-csoport, ahol a heteroatom jelentése oxigénatom, kénatom,vagy NR9a képletű csoport). Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11236998P | 1998-12-15 | 1998-12-15 | |
PCT/US1999/029591 WO2000035435A1 (en) | 1998-12-15 | 1999-12-14 | Use of a mek inhibitor for preventing transplant rejection |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104607A2 true HUP0104607A2 (hu) | 2002-04-29 |
HUP0104607A3 HUP0104607A3 (en) | 2002-12-28 |
Family
ID=22343544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104607A HUP0104607A3 (en) | 1998-12-15 | 1999-12-14 | Use of a mek inhibitor for preventing transplant rejection |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1140046A1 (hu) |
JP (1) | JP2002532414A (hu) |
KR (1) | KR20010101203A (hu) |
AU (1) | AU2180500A (hu) |
CA (1) | CA2346684A1 (hu) |
HU (1) | HUP0104607A3 (hu) |
IL (1) | IL143231A0 (hu) |
TR (1) | TR200101704T2 (hu) |
WO (1) | WO2000035435A1 (hu) |
ZA (1) | ZA200103765B (hu) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4-碘苯氨基苯氧肟酸的氧合酯 |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
AU2004283148A1 (en) | 2003-10-21 | 2005-05-06 | Warner-Lambert Company Llc | Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물 |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
EA025871B9 (ru) | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
PE20080371A1 (es) | 2006-05-19 | 2008-04-09 | Wyeth Corp | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
US8993630B2 (en) | 2008-11-10 | 2015-03-31 | Bayer Intellectual Property Gmbh | Substituted sulphonamido phenoxybenzamides |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
CN102574782B (zh) | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
CA2816188A1 (en) | 2010-10-29 | 2012-05-03 | Marion Hitchcock | Substituted phenoxypyridines |
CR20200237A (es) | 2012-10-12 | 2020-07-26 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245) |
IL278194B2 (en) | 2018-04-24 | 2023-12-01 | Translational Drug Dev Llc | Amide compounds as kinase inhibitors, compositions and methods of treatment |
WO2020142745A1 (en) * | 2019-01-04 | 2020-07-09 | Translational Drug Development, Llc | Methods of treating graft versus host disease and neoplastic disease with amide compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155110A (en) * | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
WO1996031206A2 (en) * | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
ES2229515T3 (es) * | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
WO1999034792A1 (en) * | 1998-01-06 | 1999-07-15 | The General Hospital Corporation | Use of mek1 inhibitors as protective agents against damage due to ischemia |
-
1999
- 1999-12-14 IL IL14323199A patent/IL143231A0/xx unknown
- 1999-12-14 HU HU0104607A patent/HUP0104607A3/hu unknown
- 1999-12-14 WO PCT/US1999/029591 patent/WO2000035435A1/en not_active Application Discontinuation
- 1999-12-14 AU AU21805/00A patent/AU2180500A/en not_active Abandoned
- 1999-12-14 JP JP2000587756A patent/JP2002532414A/ja active Pending
- 1999-12-14 EP EP99966203A patent/EP1140046A1/en not_active Withdrawn
- 1999-12-14 TR TR2001/01704T patent/TR200101704T2/xx unknown
- 1999-12-14 CA CA002346684A patent/CA2346684A1/en not_active Abandoned
- 1999-12-14 KR KR1020017007397A patent/KR20010101203A/ko not_active Application Discontinuation
-
2001
- 2001-05-09 ZA ZA200103765A patent/ZA200103765B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR200101704T2 (tr) | 2001-11-21 |
HUP0104607A3 (en) | 2002-12-28 |
WO2000035435A1 (en) | 2000-06-22 |
CA2346684A1 (en) | 2000-06-22 |
KR20010101203A (ko) | 2001-11-14 |
AU2180500A (en) | 2000-07-03 |
EP1140046A1 (en) | 2001-10-10 |
IL143231A0 (en) | 2002-04-21 |
ZA200103765B (en) | 2002-05-09 |
JP2002532414A (ja) | 2002-10-02 |
WO2000035435A9 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104607A2 (hu) | MEK inhibitor alkalmazása transzplantátumok kilökődésének megelőzésére | |
HUP0104693A2 (hu) | Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére | |
FI972628A (fi) | Uudet sulfonamidit | |
HUP0202593A2 (hu) | Reverz transzkriptáz inhibitor hatású benzofenonok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
ES2115163T3 (es) | Procedimiento para inhibir la proliferacion de celulas de musculos lisos y la restinosis. | |
NO20051893L (no) | Ny forbindelse | |
AU2910600A (en) | Phenyl urea and phenyl thiourea derivatives | |
NZ529682A (en) | Biologically active methylene blue derivatives | |
HUP0105113A2 (hu) | Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények | |
DE3677452D1 (de) | Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
HUP0000343A2 (hu) | 1,3-Propándiol-származékok alkalmazása szervátültetés után fellépő kilökődés megakadályozására | |
HUP0104330A2 (hu) | EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0103896A2 (hu) | Oxigéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
DK105286A (da) | B-lactamantibiotika eller salte deraf, deres fremstilling og anvendelse | |
NO924093D0 (no) | N-fenyl-2-cyano-3-hydroksykrotonsyreamidderivater og deres anvendelse som legemiddel med immunmodulatorisk egenskap | |
DK0981347T3 (da) | Anvendelsen af levobupivacain i ansigtkirurgi | |
DK0583271T3 (da) | Arylmorpholin, fremstilling og anvendelse | |
HUP0104549A2 (hu) | Imidazo-piridin szulfonamidszármazékok, és ezeket tartalmazó gyógyszerkészítmények | |
DK156655C (da) | Pyridazinoner, fremgangsmaade til fremstilling deraf, anvendelse deraf og medikamenter indeholdende pyridazinoner | |
NO964451L (no) | Röntgenkontrastblandinger inneholdende farmasöytisk akseptable leirer | |
HUP0105037A2 (hu) | Traumás stressz utáni elváltozások kezelésére alkalmas antikonvulzáns hatású származékok | |
HUP0105111A1 (hu) | 2,5-Helyettesített benzolszulfonilkarbamid- és tiokarbamidszármazékok, eljárás előállításukra, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
SE9702534D0 (sv) | Compounds | |
DK0769945T3 (da) | Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud | |
SE7806469L (sv) | Antihypertensiva kompositioner |